Cerevel Therapeutics

💊 Neuropharmaceuticals· 📍 Cambridge, USA

Overview

Cerevel Therapeutics was a clinical-stage neuroscience company developing selective receptor-targeted therapies for schizophrenia, Parkinson's disease, and epilepsy, best known for emraclidine, a muscarinic receptor agonist for schizophrenia. Cerevel was acquired by AbbVie in 2024 for approximately $8.7 billion.

More in Neuropharmaceuticals

Cortexyme Inc.

San Francisco, CA, USA

Neuralstem Inc.

Germantown, MD, USA

Neurogenix Therapeutics

Basel, Switzerland

Acadia Pharmaceuticals

San Diego, USA

Acer Therapeutics

Newton, MA, USA

Praxis Precision Medicine

Cambridge, MA, USA

Latest industry news

ReVision Implant Secures €4 Million to Advance Next-Generation Visual Neuroprosthetics

2026-07-25 · Funding

Flourish Emerges from Stealth with Bezos and Google Ventures Backing to Advance Neuroscience Therapeutics

2026-07-24 · Funding

Science Corp. Launches Prima BCI Implant in Europe, Bringing Vision Restoration to a New Market

2026-07-23 · Product

First Able-Bodied Individuals Receive Brain-Computer Implants in Landmark Expansion of BCI Eligibility

2026-07-22 · Research

Company details

Is this your company?

Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.

Claim & upgrade listing

Advertise

Reach neurotech professionals

Newsletter sponsorships, featured listings, and sponsored articles.

View packages →